Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Volsi Mimir who wrote (21795)	1/4/2000 12:52:00 PM
From: DanZ	Read Replies (3) \| Respond to of 53068

GUMM. It was just reported on Bloomberg that the CFO of Gum Tech, Bill Hemelt, bought 18,000 shares of GUMM through the exercise of options. He didn't sell any of the shares and now holds a total of 48,000 shares. The President, Gary Kehoe, exercised 100,000 options a few weeks ago and only sold 20,000 shares to help cover the cost of the exercise. He therefore, made a net purchase of 80,000 shares according to the information that has been filed. While option related, these are the first insider buys of GUMM in over a year and it should send a positive signal to investors that the officers of Gum Tech think their stock will trade higher. The company should report their first profit in many years in the fourth quarter (my estimate is 18 to 25 cents per share), and I believe that sales will exceed the previous three quarters of 1999 combined. Sales in the first quarter of 2000 are expected to at least double again as they begin international distribution of Zicam. Sales of nicotine gum from the joint venture with Swedish Match should begin in the third quarter of 2000. The independent clinical studies for Zicam (preventative and therapeutic) were due in October. It doesn't take that long to conduct a study on the common cold, and I believe that the company hasn't released the results because they submitted them publication in a medical journal. IMO, they can't report anything on the status of the studies until such time that they actually appear in print in a publication. I firmly believe that one day we will wake up to news that the studies will be published and the stock will gap over 30. IMO, GUMM has tremendous upside potential and very small downside risk. Luck all, Dan